For patients with type 2 diabetes and stage 3/4 CKD, SGLT2 inhibitors reduced the risk of the primary cardiovascular outcome by 29% (Fig 4, HR 0.71, [95% CI 0.63–0.80], I2 = 0.00%). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.